IDEXX Laboratories, Inc. vs Plug Power Inc — how do they compare? IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B), while Plug Power Inc trades at $1.75 (market cap $2.42B). The key difference: IDEXX Laboratories, Inc. is far larger — about 16.7× Plug Power Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 53,851,702). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Plug Power Inc for 41 Days on average.
| IDXX | PLUG | |
|---|---|---|
Market Cap | $40.43B | $2.42B |
Volume | 692,164 | 53,851,702 |
Sector | Health | Industrials |
52-Week High | $766.68 | $4.14 |
52-Week Low | $504.70 | $1.73 |
Typical Hold Time | 46 Days | 41 Days |
Enterprise Value | $41.32B | $3.29B |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.
The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.
Plug Power (PLUG) trades at $1.78, down 4.3% today, reflecting ongoing operational challenges despite recent strategic partnerships. The stock shows bearish technical signals with negative moving averages, while fundamentally the company continues to report significant losses with a -220.59% net income margin and negative cash flow. Recent news highlights a major 280 MW electrolyzer agreement with Arcadia eFuels and expansion in Australia/New Zealand, providing potential growth catalysts amid persistent financial headwinds.
The outlook remains challenging with substantial execution risks, though analyst consensus suggests 75% upside to the $3.13 price target. Key risks include continued cash burn, high debt levels, and competitive pressure in the hydrogen sector. Investment appeal depends on successful commercialization of green hydrogen projects and path to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →